An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Latest Information Update: 24 Jul 2024
At a glance
- Drugs Durvalumab (Primary) ; Mecbotamab vedotin (Primary) ; Ozuriftamab vedotin (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms IPROC
- 18 Jul 2024 Planned End Date changed from 1 Jun 2025 to 30 Jun 2025.
- 18 Jul 2024 Planned primary completion date changed from 1 Jun 2024 to 31 Dec 2024.
- 01 Aug 2023 According to a BioAtla media release, interim data (n=10) of this study anticipated in 2H23.